BEAM vs. BBIO, BPMC, ELAN, LEGN, TGTX, TLX, VRNA, LNTH, AXSM, and GRFS
Should you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Verona Pharma (VRNA), Lantheus (LNTH), Axsome Therapeutics (AXSM), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.
Beam Therapeutics vs.
BridgeBio Pharma (NASDAQ:BBIO) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and community ranking.
99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 18.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 4.2% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, BridgeBio Pharma had 10 more articles in the media than Beam Therapeutics. MarketBeat recorded 17 mentions for BridgeBio Pharma and 7 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 1.34 beat BridgeBio Pharma's score of 0.91 indicating that Beam Therapeutics is being referred to more favorably in the news media.
BridgeBio Pharma presently has a consensus target price of $57.09, indicating a potential upside of 69.36%. Beam Therapeutics has a consensus target price of $48.75, indicating a potential upside of 174.65%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than BridgeBio Pharma.
BridgeBio Pharma has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500.
Beam Therapeutics has a net margin of -41.07% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat Beam Therapeutics' return on equity.
Beam Therapeutics has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.
BridgeBio Pharma received 111 more outperform votes than Beam Therapeutics when rated by MarketBeat users. Likewise, 72.47% of users gave BridgeBio Pharma an outperform vote while only 59.13% of users gave Beam Therapeutics an outperform vote.
Summary
BridgeBio Pharma and Beam Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Beam Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beam Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BEAM) was last updated on 5/21/2025 by MarketBeat.com Staff
Buy BEAM Stock Free BEAM Stock Alerts